Related posts
Oil climbs, stocks moderately move13 Recession-Proof Stocks for Portfolio SafetyFlat WednesdayThis summary was created by AI, based on 16 opinions in the last 12 months.
Abbott Labs (ABT) is regarded positively by multiple experts who highlight its defensive position within the healthcare sector, especially amidst the challenges posed by tariffs and legal issues. Its diversified portfolio spans medical devices, pharmaceuticals, nutrition, and testing technologies, and is appreciated for its strong growth in medical devices and branded generics. Recent performance has been buoyed by positive earnings and raised full-year forecasts, despite facing legal hurdles related to its infant formula. Analysts forecast robust growth ahead, particularly in its diabetes monitoring products and medical devices, which have shown organic growth rates of 10-12%. The sentiment towards the stock remains optimistic, especially in light of its solid fundamentals, reasonable valuation, and a history of steady dividend growth.
Has excellent fundamentals across four businesses, including best-in-class medical devices renown in cardiology. However, they face lawsuits over their similac formula which studies show is not harmful. It's unfair. It lost a lawsuit last summer and was hit a $495 million penalty. More lawsuits are coming, though the latest decision yesterday went in Abbott's favour. Last month, federal agencies found that the formula is not at fault. Two weeks ago, ABT reported a clean top and bottom line beat and raised their full-year forecast. Shares would have rallied more without the lawsuits.
Expects it to growth topline and bottom line going forward, usually around the 10% range. Sells branded generic drugs to EMs, medical devices, infant nutrition. Diabetes monitoring product has very good growth. Likes that it's diversified, well managed. Yield close to 3%, grown for over 50 consecutive years.
Pharma is challenged on growth, whereas devices have robust growth. Its device business has grown exceptionally well, between 10-12% organically. Overhang has been unfavourable comparisons from Covid testing. Reasonable valuation for quite a good company. Yield is 2%.
(Analysts’ price target is $123.65)Abbott Labs is a American stock, trading under the symbol ABT-N on the New York Stock Exchange (ABT). It is usually referred to as NYSE:ABT or ABT-N
In the last year, 15 stock analysts published opinions about ABT-N. 2 analysts recommended to BUY the stock. 2 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Abbott Labs.
Abbott Labs was recommended as a Top Pick by on . Read the latest stock experts ratings for Abbott Labs.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
15 stock analysts on Stockchase covered Abbott Labs In the last year. It is a trending stock that is worth watching.
On 2025-04-01, Abbott Labs (ABT-N) stock closed at a price of $131.69.
He was looking at defensive healthcare names to avoid threat of tariffs. This is one name to consider, reasonable valuation but good growth profile.